Panitumumab Antitumor Activity in Patients (Pts) With Metastatic Colorectal Cancer (mCRC) Expressing Low (1–9%) or Negative (<1%) Levels of Epidermal Growth Factor Receptor (EGFr)  

J. Randolph Hecht, 1 Edith Mitchell, 1 Joaquina Baranda, 1entians Malik, 1Donald Richards, 1Lynn Navale, 1Paul D’Avirto, 1Rafael Amado  

1UCLA School of Medicine, Los Angeles, CA; 2Thomas Jefferson Medical College, Philadelphia, PA; 3University of Kansas Medical Center, Kansas City, KS; 4Loma Linda Cancer Center, Loma Linda, CA; 5Tyler Cancer Center, Tyler, TX; 6Amgen Inc., Thousand Oaks, CA

**INTRODUCTION**  
Safety follow-up visit 4 weeks after last panitumumab dose

**OBJECTIVES**  
- Primary objective: To assess the efficacy of panitumumab by: Objective response rate (ORR) by RECIST v1.1; Duration of response; Safety evaluation.
- Secondary objectives: Duration of response; Safety evaluation; Progression-free survival; Other clinically significant laboratory abnormalities.
- Endpoints: Efficacy set (N = 23), safety set (N = 88).

**KEY ELIGIBILITY CRITERIA**  
- Pathologic diagnosis of CRC
- Age ≥ 18 years
- > 3 weeks from primary diagnosis or metastatic disease
- No more than 6 months from tumor progression to study
- No prior irinotecan or bevacizumab
- No prior radiation therapy

**ANALYSIS SETS**  
- Efficacy set (N = 23), safety set (N = 88)
- Duration of response: from initiation of treatment to date of last assessment.

**RESULTS**  
- ORR: 13% partial response, 3% complete response
- Duration of response: median 18.5 weeks
- Safety: 100% patients with any grade skin-related toxicity, 81% patients with grade 3 skin-related toxicity

**CONCLUSIONS**  
- In this interim analysis, panitumumab 6 mg/kg Q2W had antitumor activity in patients with or without EGFr tumor membrane expression
- Objective response rates were: 13% partial response, 3% complete response
- Other clinically significant laboratory abnormalities: skin-related toxicities
- Treatment was well tolerated

**REFERENCES**  
- Joaquina Baranda, Rafael Amado, Loma Linda Cancer Center, Loma Linda, CA; 4Amgen Inc., Thousand Oaks, CA

**DESIGN AND METHODS**  
- Phase III, multicenter, open-label study
- Panitumumab was administered at 6 mg/kg Q2W until disease progression or drug intolerance
- Disease progression was assessed by RECIST v1.1 criteria

**TABLES**  
- Table 1: Demographics of Patients
- Table 2: Efficacy Analysis
- Table 3: Summary of Adverse Events
- Table 4: Progression-Free Survival in the Efficacy Set}

**ACKNOWLEDGMENTS**  
- The authors wish to thank the patients and their families for their participation in this study.